{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:03:07Z","timestamp":1786993387752,"version":"build-2736575974"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.jsat.2022.108827","type":"journal-article","created":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T21:48:23Z","timestamp":1655329703000},"page":"108827","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Factors associated with clinician treatment recommendations for patients with a new diagnosis of opioid use disorder"],"prefix":"10.1016","volume":"141","author":[{"given":"Lewei (Allison)","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria D.","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Macleod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy S.B.","family":"Bohnert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Lagisetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsat.2022.108827_bb0005","article-title":"Geographic distribution of providers with a DEA waiver to prescribe buprenorphine for the treatment of opioid use disorder: A 5-year update","author":"Andrilla","year":"2018","journal-title":"The Journal of Rural Health: Official Journal of the American Rural Health Association and the National Rural Health Care Association"},{"key":"10.1016\/j.jsat.2022.108827_bb0010","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jsat.2014.12.011","article-title":"Discontinuation of buprenorphine maintenance therapy: Perspectives and outcomes","volume":"52","author":"Bentzley","year":"2015","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"3","key":"10.1016\/j.jsat.2022.108827_bb0015","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s11606-017-4163-2","article-title":"Increased rates of documented alcohol counseling in primary care: More counseling or just more documentation?","volume":"33","author":"Berger","year":"2018","journal-title":"Journal of General Internal Medicine"},{"issue":"34","key":"10.1016\/j.jsat.2022.108827_bb0020","doi-asserted-by":"crossref","first-page":"737","DOI":"10.15585\/mmwr.mm6834a2","article-title":"Changes in opioid-involved overdose deaths by opioid type and presence of benzodiazepines, cocaine, and Methamphetamine\u201425 states, July-December 2017 to January-June 2018","volume":"68","author":"Gladden","year":"2019","journal-title":"MMWR. Morbidity and Mortality Weekly Report"},{"key":"10.1016\/j.jsat.2022.108827_bb0025","article-title":"The HEALing (Helping to End Addiction Long-term SM) Communities Study: Protocol for a cluster randomized trial at the community level to reduce opioid overdose deaths through implementation of an integrated set of evidence-based practices","volume":"217","author":"HEALing Communities Study Consortium","year":"2020","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2022.108827_bb0030","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jsat.2019.06.008","article-title":"State targeted response to the opioid crisis grants (opioid STR) program: Preliminary findings from two case studies and the national cross-site evaluation","volume":"108","author":"High","year":"2020","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"5","key":"10.1016\/j.jsat.2022.108827_bb0035","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1111\/add.14878","article-title":"The rise in non-fatal and fatal overdoses involving stimulants with and without opioids in the United States","volume":"115","author":"Hoots","year":"2020","journal-title":"Addiction (Abingdon, England)"},{"key":"10.1016\/j.jsat.2022.108827_bb0040","article-title":"Validity of incident opioid use disorder (OUD) diagnoses in administrative data: A chart verification study","author":"Howell","year":"2020","journal-title":"Journal of General Internal Medicine"},{"issue":"8","key":"10.1016\/j.jsat.2022.108827_bb0045","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.2105\/AJPH.2015.302664","article-title":"National and state treatment need and capacity for opioid agonist medication-assisted treatment","volume":"105","author":"Jones","year":"2015","journal-title":"American Journal of Public Health"},{"key":"10.1016\/j.jsat.2022.108827_bb0050","doi-asserted-by":"crossref","DOI":"10.15585\/mmwr.mm6817a3","article-title":"Drug overdose deaths involving cocaine and psychostimulants with abuse potential\u2014United States, 2003\u20132017","volume":"68","author":"Kariisa","year":"2019","journal-title":"MMWR. Morbidity and Mortality Weekly Report"},{"issue":"1","key":"10.1016\/j.jsat.2022.108827_bb0055","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/ADM.0000000000000360","article-title":"Physicians\u2019 decision-making when implementing buprenorphine with new patients: Conjoint analyses of data from a cohort of current prescribers","volume":"12","author":"Knudsen","year":"2018","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.jsat.2022.108827_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108583","article-title":"Identifying individuals with opioid use disorder: Validity of international classification of diseases diagnostic codes for opioid use, dependence and abuse","volume":"221","author":"Lagisetty","year":"2021","journal-title":"Drug and Alcohol Dependence"},{"issue":"9","key":"10.1016\/j.jsat.2022.108827_bb0065","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/jamapsychiatry.2019.0876","article-title":"Buprenorphine treatment divide by Race\/Ethnicity and payment","volume":"76","author":"Lagisetty","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jsat.2022.108827_bb0070","doi-asserted-by":"crossref","DOI":"10.7326\/M17-3107","article-title":"Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: A cohort study","author":"Larochelle","year":"2018","journal-title":"Annals of Internal Medicine"},{"issue":"9","key":"10.1016\/j.jsat.2022.108827_bb0075","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1001\/jamapsychiatry.2016.1390","article-title":"Use of opioid agonist therapy for medicare patients in 2013","volume":"73","author":"Lembke","year":"2016","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"10.1016\/j.jsat.2022.108827_bb0080","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/ajad.12705","article-title":"Commentary: Providing technical assistance for the state targeted response for opioid use disorders: Time is of the essence","volume":"27","author":"Levin","year":"2018","journal-title":"The American Journal on Addictions"},{"key":"10.1016\/j.jsat.2022.108827_bb0085","article-title":"Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration","author":"Lin","year":"2020","journal-title":"Addiction (Abingdon, England)"},{"issue":"2","key":"10.1016\/j.jsat.2022.108827_bb0090","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0740-5472(02)00257-X","article-title":"Buprenorphine: Blending practice and research","volume":"23","author":"Ling","year":"2002","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2022.108827_bb0095","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"2","author":"Mattick","year":"2014","journal-title":"The Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.jsat.2022.108827_bb0100","article-title":"Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population","author":"Morgan","year":"2017","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"9","key":"10.1016\/j.jsat.2022.108827_bb0105","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/jama.2017.0001","article-title":"Opioid agonist treatment for patients with dependence on prescription opioids","volume":"317","author":"Nielsen","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.jsat.2022.108827_bb0110","doi-asserted-by":"crossref","DOI":"10.1111\/ajad.12861","article-title":"Comparison of opioid use disorder among male veterans and non-veterans: Disorder rates, socio-demographics, co-morbidities, and quality of life","author":"Rhee","year":"2019","journal-title":"The American Journal on Addictions"},{"issue":"14","key":"10.1016\/j.jsat.2022.108827_bb0115","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1001\/jama.2015.10345","article-title":"Changes in substance abuse treatment use among individuals with opioid use disorders in the United States, 2004\u20132013","volume":"314","author":"Saloner","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jsat.2022.108827_bb0120","article-title":"Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1016\/j.jsat.2022.108827_bb0125","series-title":"Medications to treat opioid use disorder. Treatment improvement protocol (TIP) series 63, full document. (HHS Publication No. (SMA) 18-5063FULLDOC.)","author":"Substance Abuse and Mental Health Services Administration","year":"2018"},{"issue":"2","key":"10.1016\/j.jsat.2022.108827_bb0130","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1176\/ps.2007.58.2.266","article-title":"How are substance use disorders addressed in VA psychiatric and primary care Settings? Results of a National Survey","volume":"58","author":"Tracy","year":"2007","journal-title":"Psychiatric Services"},{"issue":"3","key":"10.1016\/j.jsat.2022.108827_bb0135","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1080\/08897077.2018.1509251","article-title":"Underutilization of the current clinical capacity to provide buprenorphine treatment for opioid use disorders within the veterans health administration","volume":"39","author":"Valenstein-Mah","year":"2018","journal-title":"Substance Abuse"},{"issue":"6","key":"10.1016\/j.jsat.2022.108827_bb0140","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1097\/MLR.0b013e31819432e5","article-title":"A modification of the elixhauser comorbidity measures into a point system for hospital death using administrative data","volume":"47","author":"van Walraven","year":"2009","journal-title":"Medical Care"},{"issue":"22","key":"10.1016\/j.jsat.2022.108827_bb0145","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMp1402780","article-title":"Medication-assisted therapies\u2014Tackling the opioid-overdose epidemic","volume":"370","author":"Volkow","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1016\/j.jsat.2022.108827_bb0150","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1093\/jamia\/ocaa027","article-title":"How accurate is the medical record? A comparison of the physician\u2019s note with a concealed audio recording in unannounced standardized patient encounters","volume":"27","author":"Weiner","year":"2020","journal-title":"Journal of the American Medical Informatics Association: JAMIA"},{"issue":"4","key":"10.1016\/j.jsat.2022.108827_bb0155","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1748-0361.2010.00298.x","article-title":"Defining \u201crural\u201d for veterans\u2019 health care planning","volume":"26","author":"West","year":"2010","journal-title":"The Journal of Rural Health: Official Journal of the American Rural Health Association and the National Rural Health Care Association"},{"issue":"1","key":"10.1016\/j.jsat.2022.108827_bb0160","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/acer.14239","article-title":"Using death certificates to explore changes in alcohol-related mortality in the United States, 1999 to 2017","volume":"44","author":"White","year":"2020","journal-title":"Alcoholism: Clinical and Experimental Research"},{"issue":"1","key":"10.1016\/j.jsat.2022.108827_bb0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/00952990.2018.1546862","article-title":"Development of a Cascade of care for responding to the opioid epidemic","volume":"45","author":"Williams","year":"2019","journal-title":"The American Journal of Drug and Alcohol Abuse"},{"key":"10.1016\/j.jsat.2022.108827_bb0170","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jsat.2018.06.001","article-title":"Developing an opioid use disorder treatment cascade: A review of quality measures","volume":"91","author":"Williams","year":"2018","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"11","key":"10.1016\/j.jsat.2022.108827_bb0175","doi-asserted-by":"crossref","first-page":"290","DOI":"10.15585\/mmwr.mm6911a4","article-title":"Drug and opioid-involved overdose deaths\u2014United States, 2017\u20132018","volume":"69","author":"Wilson","year":"2020","journal-title":"MMWR. Morbidity and Mortality Weekly Report"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S074054722200109X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S074054722200109X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:56:13Z","timestamp":1760039773000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S074054722200109X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":35,"alternative-id":["S074054722200109X"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2022.108827","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factors associated with clinician treatment recommendations for patients with a new diagnosis of opioid use disorder","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2022.108827","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108827"}}